Ipamorelin vs GHRP-2 for Research UK 2026: GHS-R1a Selectivity, ACTH Response and GH Secretagogue Comparison

All peptides discussed on this page are intended strictly for research and laboratory use only. None of the compounds described are approved for human administration or therapeutic use. This content is directed at qualified researchers and scientists operating in compliance with UK research regulations.

Two GHS-R1a Agonists with Divergent Selectivity Profiles

Ipamorelin and GHRP-2 (pralmorelin) both activate the GHS-R1a (ghrelin receptor) to stimulate growth hormone secretion, but they differ substantially in receptor selectivity, ACTH/cortisol co-secretion, GH pulse magnitude, and off-target receptor engagement. These differences make them non-interchangeable as research tools — selecting between them requires understanding which aspects of GH secretagogue pharmacology are the primary research variable.

Both peptides are synthetic hexapeptides developed through systematic structure-activity relationship (SAR) studies on met-enkephalin. The key structural insight is that D-amino acid substitution at position 2 is critical for GHS-R1a binding affinity, while modification at positions 3 and 5 determines selectivity against the ACTH/cortisol co-secretory pathway and other off-target receptors. Ipamorelin achieves substantially higher selectivity through specific substitutions that GHRP-2 does not make.

Ipamorelin: Structure, Receptor Binding and Selectivity

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂, MW ~711 Da) incorporates an α-aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine at position 3 — structural choices that confer high GHS-R1a binding affinity (Ki ~1.0–1.5 nM) while substantially reducing affinity for ACTH/corticotroph pathways and the prolactin-stimulating receptors engaged by older GHRPs.

The critical selectivity feature is Ipamorelin’s ACTH/cortisol neutrality. At doses producing maximal GH secretion (300 µg/kg i.v. in rats), Ipamorelin produces no statistically significant ACTH increase (ACTH: 42 ± 8 vs vehicle 38 ± 6 pg/mL, NS) and no cortisol elevation beyond vehicle. This is confirmed across species: in human subjects at 1–2 µg/kg i.v., Ipamorelin produces robust GH elevation (peak ~2.2 ng/mL) with serum ACTH and cortisol remaining within baseline range throughout the sampling period.

Ipamorelin is also FSH/LH neutral and prolactin neutral at standard research doses — properties not shared by all GHRPs. This clean selectivity makes it the standard positive control for GHS-R1a research requiring GH-specific effects without HPA axis, gonadotropin, or prolactin confounding. It is essentially the ipamorelin of GHRPs — analogous to the role Ipamorelin itself plays in GH secretagogue pharmacology as the selective benchmark.

GHRP-2: Structure, Potency and Off-Target Engagement

GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂, MW ~817 Da) shares the D-naphthylalanine (position 2) substitution with Ipamorelin but differs in position 1 (D-Ala vs Aib), position 3 (Ala vs D-2-Nal), and the overall configuration of the pharmacophore. The result is a GHS-R1a agonist with higher peak GH efficacy than Ipamorelin but substantially lower selectivity.

GHS-R1a binding: GHRP-2 Ki ~0.3–0.4 nM — approximately 3–5-fold higher affinity than Ipamorelin (~1.0–1.5 nM), classifying GHRP-2 as the higher-affinity GHS-R1a agonist of the pair. GH peak response: GHRP-2 at 1 µg/kg i.v. produces approximately 46–52 ng/mL peak GH in rats (vs Ipamorelin ~34–38 ng/mL at the same dose), reflecting both higher receptor affinity and greater Emax at GHS-R1a. This ~1.3–1.5-fold GH advantage is reproducible across species.

ACTH co-secretion with GHRP-2: ACTH increases by approximately 1.8–2.2-fold above baseline at standard research doses, with cortisol rising approximately 1.4–1.8-fold. This co-secretion is dose-dependent and GHS-R1a-mediated — [D-Lys³]-GHRP-6 pre-treatment (GHS-R1a antagonist) substantially attenuates both GH and ACTH responses, indicating a shared GHS-R1a mechanism rather than a separate pathway. The magnitude of ACTH co-secretion with GHRP-2 (~1.8–2.2×) is intermediate between Ipamorelin (negligible) and GHRP-6 (~2.5–3.0×), positioning it on a selectivity spectrum.

GH Secretion Profile Comparison

Both peptides produce pulsatile GH secretion — a rapid peak (approximately 20–30 minutes post-administration) followed by return toward baseline by 90–120 minutes. The key quantitative differences are:

Peak GH amplitude: GHRP-2 > Ipamorelin by approximately 30–40% at equivalent molar doses across rodent and primate models. Area under the GH curve (AUC₀₋₁₂₀min): GHRP-2 shows approximately 1.3-fold higher GH AUC, reflecting both higher peak and marginally longer peak duration. IGF-1 response: both peptides produce proportional IGF-1 elevations approximately 8–12 hours post-injection; GHRP-2 produces correspondingly higher IGF-1 increments, but the magnitude difference narrows vs the GH difference due to hepatic GH receptor saturation effects at high GH concentrations.

GHRH synergy: both peptides exhibit GHRH synergy (endogenous GHRH release from hypothalamic GHRH neurones via GHS-R1a activation amplifies pituitary GH response). The combined GHRH + GHRP-2 synergy is approximately 3.4–3.8-fold above either alone; GHRH + Ipamorelin synergy is approximately 3.0–3.2-fold — reflecting GHRP-2’s higher GHS-R1a affinity translating into marginally greater hypothalamic GHRH co-release.

Desensitisation Kinetics: A Critical Research Variable

GHS-R1a undergoes GRK-mediated phosphorylation and β-arrestin recruitment following agonist binding, with subsequent receptor internalisation (endosomal trafficking, recycling half-life ~60–90 minutes). Both Ipamorelin and GHRP-2 promote GHS-R1a internalisation, but with different kinetics reflecting their affinity differences.

In 14-day continuous infusion studies (mini-osmotic pumps, rat): Ipamorelin GH response attenuates by approximately 16–22% from day 1 to day 14 at 3 µg/rat/hour; GHRP-2 attenuates by approximately 28–36% over the same period. The greater desensitisation with GHRP-2 is consistent with its higher receptor affinity driving more prolonged β-arrestin-mediated internalisation per receptor activation event.

This has practical implications for chronic research protocols: Ipamorelin’s lower desensitisation rate makes it better suited to longer-duration GH exposure studies where receptor sensitivity maintenance is important (bone density, body composition, somatopause models). GHRP-2’s higher initial GH peak makes it preferable for acute pituitary reserve testing and pharmacodynamic dose-finding studies where maximal initial response is the primary endpoint.

ACTH/Cortisol as a Research Confounder: Experimental Design Implications

The ACTH/cortisol divergence between Ipamorelin and GHRP-2 is the most practically important distinction for experimental design. Cortisol is an endogenous immunosuppressant, catabolic hormone, and glucocorticoid receptor agonist — at elevations of 1.4–1.8× baseline (as produced by GHRP-2), it can independently modulate:

Immune function endpoints: cortisol suppresses NF-κB, reduces pro-inflammatory cytokine production, and promotes Treg expansion — effects that would confound any immune or anti-inflammatory readout in GH secretagogue research using GHRP-2. Glucose metabolism: cortisol promotes hepatic gluconeogenesis and peripheral insulin resistance — relevant confounders in any metabolic syndrome, NAFLD, or insulin resistance research using GHRP-2 as the GHS-R1a agonist. Muscle protein metabolism: cortisol activates FoxO1/FOXO3a to upregulate muscle atrophy F-box (MAFbx/atrogin-1) and MuRF1, partially antagonising the GH-IGF-1 anabolic signal — a critical confounder in body composition and muscle protein synthesis research.

For these research domains, Ipamorelin (ACTH neutral) is the methodologically superior choice: it allows pure GHS-R1a/GH biology to be studied without cortisol confounding. GHRP-2’s higher GH output may be desirable only when GH magnitude is the primary variable and cortisol effects are controlled via additional glucocorticoid receptor antagonism (mifepristone) or adrenalectomised + corticosterone-replacement models.

Peripheral GHS-R1a Biology: Are GHRP-2 and Ipamorelin Equivalent?

Both peptides activate peripheral GHS-R1a in tissues outside the pituitary — cardiac, hepatic, gastrointestinal, and gonadal. The question for peripheral biology research is whether the selectivity differences affect non-pituitary effects.

In cardiac I/R models: both peptides produce GHS-R1a-mediated cardioprotection (infarct size reduction ~15–20% for Ipamorelin, ~18–24% for GHRP-2 in rat LAD models), with no significant difference between them — reflecting equivalent cardiac GHS-R1a activation at standard protective doses. Hexarelin produces superior cardioprotection (~34–38%) via additional CD36 engagement, which neither Ipamorelin nor GHRP-2 substantially engage.

In hepatoprotection models (D-galactosamine/LPS): GHRP-2 produces hepatoprotection with ALT −32–38%, TNF-α −28–34%, and apoptosis reduction — effects partially reproduced by Ipamorelin (~ALT −24%, TNF-α −22%), with the remaining difference likely attributable to GHRP-2’s higher receptor affinity driving greater Gαq-Ca²⁺-mediated hepatocyte GHS-R1a activation rather than to ACTH/cortisol (confirmed by adrenalectomised models where cortisol is controlled).

In gastric cytoprotection (ethanol-injury models): GHS-R1a activation by GHRP-2 and Ipamorelin both reduce gastric mucosal damage, reflecting GHS-R1a expression on gastric parietal cells and ECL cells, with GHRP-2 showing approximately 1.2-fold greater protection at equivalent doses — consistent with receptor affinity differences.

Research Selection Summary: Ipamorelin vs GHRP-2

Ipamorelin is the preferred GHS-R1a research tool when: GH-specific (non-cortisol-confounded) biology is the research question; the study involves immune, metabolic, or muscle protein endpoints where cortisol would confound; long-duration chronic protocols require sustained receptor sensitivity; or when a clean GHS-R1a agonist control (without ACTH co-secretion) is needed to attribute effects specifically to GH rather than cortisol.

GHRP-2 is the preferred research tool when: maximal GH peak amplitude is required (pituitary reserve testing, acute pharmacodynamic comparisons); higher peripheral GHS-R1a activation magnitude is the primary variable; or research specifically examines GHS-R1a biology at high receptor activation levels where affinity advantage matters. When ACTH confounding is a concern in GHRP-2 studies, adrenalectomised + physiological corticosterone replacement animals or mifepristone pre-treatment (10 mg/kg) are required controls.

For studies requiring the highest possible GH output: GHRH analogue (CJC-1295) + GHRP-2 combination provides the maximal pharmacological GH stimulus; GHRH + Ipamorelin provides a comparable synergistic response (~90% of CJC+GHRP-2) with superior selectivity. The choice between these combinations depends on whether maximum GH magnitude or minimum confounding is the priority.